Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Feb 21;14(1):104.
doi: 10.1186/ar3688.

Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off

Yusuf Yazici
Editorial

Abatacept versus other biologics in methotrexate inadequate responders with rheumatoid arthritis: you like tomato and I like tomahto... let's call the whole thing off

Yusuf Yazici. Arthritis Res Ther. .

Abstract

In the absence of head-to-head trials, analysis of available data from randomized clinical trials allows for comparison of the efficacy of biologic agents for the treatment of rheumatoid arthritis. Methotrexate (MTX) inadequate responder trials provide data suggesting no major differences among any of the biologic agents, which is also confirmed in MTX naive population trials, when available, possibly a more reliable comparison group. The decision to pick one over the other should focus on safety, long-term survival of the drug and ease of use, which is for the most part influenced by patient preferences.

PubMed Disclaimer

Comment on

References

    1. Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M, Drost P, Bergman G. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther. 2011;13:R204. doi: 10.1186/ar3537. - DOI - PMC - PubMed
    1. Yazici Y, Swearingen CJ, Nadkarni A, Rosenblatt L. Comparative efficacy and tolerability of biologic therapies in early rheumatoid arthritis utilizing a Bayesian approach [abstract] Arthritis Rheum. 2011;63(Suppl S10):S484.
    1. Yazici Y, Filopoulos M, Swearingen CJ. Comparative effectiveness and time to response among adalimumab, abatacept, etanercept and infliximab for the treatment of rheumatoid arthritis in a real world routine care registry. Arthritis Rheum. 2011;63(Suppl):S873.
    1. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. J Rheumatol. 2003;30:1138–1146. - PubMed
    1. Gogus F, Yazici Y, Yazici H. Inclusion criteria as widely used for rheumatoid arthritis clinical trials: patient eligibility in a Turkish cohort. Clin Exp Rheumatol. 2005;23:681–684. - PubMed

MeSH terms